Alcon A global leader in eye care

Dedicated to helping people see brilliantly, Alcon’s business is built on a solid foundation of market-leading eye care expertise and deep, long-standing relationships with eye care professionals.

With a 70-plus-year heritage and complementary businesses in Surgical and Vision Care, Alcon is working in 74 countries and serving patients in more than 140. In 2018, Alcon’s Surgical Sales totaled $4.0 billion and Vision Care sales totaled $3.1 billion. The company is also an innovation leader with 1,200 dedicated R&D employees, more than 100 projects in the pipeline and one of the largest R&D commitments in the market.

Alcon offers the widest array of eye care offerings in the industry with products that can treat the entire eye at each stage of life. It is the global market leader in Surgical with best-in-class equipment platforms and the largest installed base of surgical equipment, including equipment for cataract, vitreoretinal and refractive surgery, as well as advanced technology intraocular lenses. Moreover Alcon is a close number 2 market leader in Vision Care offering a broad range of daily disposable, reusable and color-enhancing contact lenses and a comprehensive portfolio of ocular health products. These include products for dry eye, contact lens care and ocular allergies, as well as ocular vitamins and redness relievers.

Alcon is committed to continuing to be among the market leaders in eye care R&D investment, with plans to invest more than $2.5 billion in the next five years. Its ongoing projects include over 35 that have achieved positive proof of concept or are undergoing regulatory review. In Surgical, the company is focused on combining new IOL technologies with advanced surgical equipment utilized for diagnostics, intra/post-op and visualization. In the IOL space it wants to continue to lead in material, optics and delivery systems - the three key aspects that determine the performance of an IOL. As for the equipment portfolio, Alcon strives for the seamless integration of all equipment by harmonizing the user interfaces and cloud based digital connectivity. It also wants to ensure 3D visualization becomes the new standard of care during both cataract and vitreoretinal surgery. In Vision Care, the company is accelerating innovation with a strong

pipeline of products to address specific consumer needs such as a next generation water gradient lens and novel designs for presbyopia correction. It will be launching new SYSTANE ® products and technology to address physician and consumer preferences as well as to complete its global product offering.

In addition to its in-house R&D capabilities, Alcon considers external innovation opportunities and routinely screen for companies developing emerging technologies that could enhance its existing product offerings or lead to innovative new products. The company maintains an extensive network of relationships with top-tier scientists in academia and with leading healthcare professionals. It has completed more than 20 BD&L transactions since 2016, including Philips Healthcare to create a new digital health platform – SMART Suite by Alcon – to streamline, simplify and improve cataract surgery for surgeons and patients.

Today Alcon has a unique opportunity to grow in the large, attractive and expanding $23 billion global eye care device market (Surgical: $9 billion; Vision Care $14 billion). The approximate $23 billion-per-year eye care marketplace is projected to grow 4 percent annually over the next five years, driven by an aging population and rising wealth in emerging markets.

Alcon NV Medialaan 36 - B-1800 Vilvoorde Tel.: +32 (0)2 754 33 02 Email: benelux@alcon.com https://www.alcon.com